Was hoping for positive news and fearing the opposite.
"Low-dose AGEN1181 monotherapy demonstrated a confirmed complete response in a patient with difficult-to-treat endometrial cancer"
This is incredible though obviously a sample of one does not yield a statistically valid result.
The positive news on Balstilimab and zalifrelimab is also great news.
Added more shares this morning. I now try never to add shares in small pharma companies other than on days of positive news releases accompanied by the mindless sell-the-news pps hit.